28 décembre, 2006 14:57
Diabetes Forum: BioCritique Articles
Recently posted articles in the Diabetes Forum on Biocritique:
Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study.
J Lindström, P Ilanne-Parikka, M Peltonen, S Aunola, JG Eriksson, K Hemiö, H Hämäläinen, P Härkönen, S Keinänen-Kiukaanniemi, M Laakso, A Louheranta, M Mannelin, M Paturi, J Sundvall, TT Valle, M Uusitupa, J Tuomilehto
Lancet 2006 11;368(9548):1673-9
http://www.biocritique.com/v.cfm?pmid=17098085
Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks.
KM Gadde, DB Allison
Circulation 2006 8;114(9):974-84
http://www.biocritique.com/v.cfm?pmid=16940206
Gout and the risk of acute myocardial infarction. E Krishnan, JF Baker, DE Furst, HR Schumacher Arthritis Rheum 2006 8;54(8):2688-96
http://www.biocritique.com/v.cfm?pmid=16871533
Influence of insulin resistance and body mass index at age 13 on systolic blood pressure, triglycerides, and high-density lipoprotein cholesterol at age 19.
AR Sinaiko, J Steinberger, A Moran, CP Hong, RJ Prineas, DR Jacobs
Hypertension 2006 10;48(4):730-6
http://www.biocritique.com/v.cfm?pmid=16923995
Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy.
JJ Goldberger, H Subacius, A Schaechter, A Howard, R Berger, A Shalaby, J Levine, AH Kadish
J Am Coll Cardiol 2006 9;48(6):1228-33
http://www.biocritique.com/v.cfm?pmid=16979011
Midlife body mass index and hospitalization and mortality in older age.
LL Yan, ML Daviglus, K Liu, J Stamler, R Wang, A Pirzada, DB Garside, AR Dyer, L Van Horn, Y Liao, JF Fries, P Greenland
JAMA 2006 1;295(2):190-8
http://www.biocritique.com/v.cfm?pmid=16403931
Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial.
PB Watkins, N Kaplowitz, JT Slattery, CR Colonese, SV Colucci, PW Stewart, SC Harris
JAMA 2006 7;296(1):87-93
http://www.biocritique.com/v.cfm?pmid=16820551
Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
RJ Heine, LF Van Gaal, D Johns, MJ Mihm, MH Widel, RG Brodows
Ann Intern Med 2005 10;143(8):559-69
http://www.biocritique.com/v.cfm?pmid=16230722
Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes.
H Linnebjerg, PA Kothare, Z Skrivanek, A Peña, M Atkins, CS Ernest, ME Trautmann
Diabet Med 2006 3;23(3):240-5
http://www.biocritique.com/v.cfm?pmid=16492205
Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.
FX Pi-Sunyer, LJ Aronne, HM Heshmati, J Devin, J Rosenstock
JAMA 2006 2;295(7):761-75
http://www.biocritique.com/v.cfm?pmid=16478899
